Val J. Watts - Publications

MCMP Purdue University, West Lafayette, IN, United States 

107 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Ostrom KF, LaVigne JE, Brust TF, Seifert R, Dessauer CW, Watts VJ, Ostrom RS. Physiological Roles of Mammalian Transmembrane Adenylyl Cyclase Isoforms. Physiological Reviews. PMID 34698552 DOI: 10.1152/physrev.00013.2021  0.329
2019 Ding Z, Ejendal KFK, Soto Velasquez M, Hayes MP, Santoro N, Larsen MJ, Watts VJ. Genome-wide siRNA screening reveals a role for Cullin3-RING ligase signaling in heterologous sensitization of adenylyl cyclase. The Journal of Pharmacology and Experimental Therapeutics. PMID 31857349 DOI: 10.1124/Jpet.119.261255  0.326
2019 Doyle TB, Muntean BS, Ejendal KF, Hayes MP, Soto-Velasquez M, Martemyanov KA, Dessauer CW, Hu CD, Watts VJ. Identification of Novel Adenylyl Cyclase 5 (AC5) Signaling Networks in D and D Medium Spiny Neurons using Bimolecular Fluorescence Complementation Screening. Cells. 8. PMID 31752385 DOI: 10.3390/Cells8111468  0.499
2019 Doyle TB, Hayes MP, Chen DH, Raskind WH, Watts VJ. Functional characterization of AC5 gain-of-function variants: Impact on the molecular basis of ADCY5-related dyskinesia. Biochemical Pharmacology. PMID 30772269 DOI: 10.1016/J.Bcp.2019.02.005  0.557
2019 Baldwin TA, Li Y, Brand CS, Watts VJ, Dessauer CW. Insights Into The Regulatory Properties of Human Adenylyl Cyclase Type 9. Molecular Pharmacology. PMID 30696718 DOI: 10.1124/Mol.118.114595  0.308
2018 Hill CA, Sharan S, Watts VJ. Genomics, GPCRs and new targets for the control of insect pests and vectors. Current Opinion in Insect Science. 30: 99-106. PMID 30553493 DOI: 10.1016/J.Cois.2018.08.010  0.328
2018 Kaur J, Soto-Velasquez M, Ding Z, Ghanbarpour A, Lill MA, van Rijn RM, Watts VJ, Flaherty DP. Optimization of a 1,3,4-oxadiazole series for inhibition of Ca/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain. European Journal of Medicinal Chemistry. 162: 568-585. PMID 30472604 DOI: 10.1016/J.Ejmech.2018.11.036  0.37
2018 Česnek M, Skácel J, Jansa P, Dračínský M, Šmídková M, Mertlíková-Kaiserová H, Soto-Velasquez MP, Watts VJ, Janeba Z. Nucleobase modified adefovir (PMEA) analogues as potent and selective inhibitors of adenylate cyclases from Bordetella pertussis and Bacillus anthracis. Chemmedchem. PMID 29968968 DOI: 10.1002/Cmdc.201800332  0.334
2018 Soto-Velasquez M, Hayes MP, Alpsoy A, Dykhuizen EC, Watts VJ. A Novel CRISPR/Cas9-Based Cellular Model to Explore Adenylyl Cyclase and Cyclic AMP Signaling. Molecular Pharmacology. PMID 29950405 DOI: 10.1124/Mol.118.111849  0.459
2017 Frydrych J, Skácel J, Šmídková M, Mertlíková-Kaiserová H, Dračínský M, Gnanasekaran R, Lepšík M, Soto-Velasquez M, Watts VJ, Janeba Z. Synthesis of α-branched acyclic nucleoside phosphonates as potential inhibitors of bacterial adenylate cyclases. Chemmedchem. PMID 29235265 DOI: 10.1002/Cmdc.201700715  0.361
2017 Hayes MP, Soto-Velasquez M, Fowler CA, Watts VJ, Roman DL. Identification of FDA-approved small molecules capable of disrupting the Calmodulin-Adenylyl Cyclase 8 interaction through direct binding to Calmodulin. Acs Chemical Neuroscience. PMID 28968502 DOI: 10.1021/Acschemneuro.7B00349  0.354
2017 Brust TF, Alongkronrusmee D, Soto-Velasquez M, Baldwin TA, Ye Z, Dai M, Dessauer CW, van Rijn RM, Watts VJ. Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. Science Signaling. 10. PMID 28223412 DOI: 10.1126/Scisignal.Aah5381  0.44
2017 Rana N, Conley JM, Soto-Velasquez M, Leon F, Cutler SJ, Watts VJ, Lill MA. Molecular Modeling Evaluation of the Enantiomers of a Novel Adenylyl Cyclase 2 Inhibitor. Journal of Chemical Information and Modeling. PMID 28068084 DOI: 10.1021/Acs.Jcim.6B00454  0.381
2016 Xu RQ, Watts VJ. [Research progress of Gα(i/o)-coupled receptor-mediated supersensitization of adenylyl cyclase]. Yao Xue Xue Bao = Acta Pharmaceutica Sinica. 51: 1349-55. PMID 29924508  0.371
2016 Břehová P, Šmídková M, Skácel J, Dračínský M, Mertlíková-Kaiserová H, Velasquez MP, Watts VJ, Janeba Z. Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases. Chemmedchem. PMID 27775243 DOI: 10.1002/Cmdc.201600439  0.335
2016 Hill CA, Doyle T, Nuss AB, Ejendal KF, Meyer JM, Watts VJ. Comparative pharmacological characterization of D1-like dopamine receptors from Anopheles gambiae, Aedes aegypti and Culex quinquefasciatus suggests pleiotropic signaling in mosquito vector lineages. Parasites & Vectors. 9: 192. PMID 27048546 DOI: 10.1186/S13071-016-1477-6  0.508
2015 ?esnek M, Jansa P, Šmídková M, Mertlíková-Kaiserová H, Dra?ínský M, Brust TF, Pávek P, Trejtnar F, Watts VJ, Janeba Z. Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis. Chemmedchem. PMID 26136378 DOI: 10.1002/Cmdc.201500183  0.329
2015 Brust TF, Conley JM, Watts VJ. Gαi/o-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later. European Journal of Pharmacology. PMID 25981304 DOI: 10.1016/J.Ejphar.2015.05.014  0.452
2015 Nuss AB, Ejendal KF, Doyle TB, Meyer JM, Lang EG, Watts VJ, Hill CA. Dopamine receptor antagonists as new mode-of-action insecticide leads for control of Aedes and Culex mosquito vectors. Plos Neglected Tropical Diseases. 9: e0003515. PMID 25793586 DOI: 10.1371/Journal.Pntd.0003515  0.444
2015 Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ. Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways. The Journal of Pharmacology and Experimental Therapeutics. 352: 480-93. PMID 25539635 DOI: 10.1124/Jpet.114.220293  0.462
2015 Brust TF, Hayes MP, Roman DL, Watts VJ. New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling. Biochemical Pharmacology. 93: 85-91. PMID 25449598 DOI: 10.1016/J.Bcp.2014.10.014  0.547
2015 Conley JM, Meyer JM, Nuss AB, Doyle TB, Savinov SN, Hill CA, Watts VJ. Evaluation of AaDOP2 receptor antagonists reveals antidepressants and antipsychotics as novel lead molecules for control of the yellow fever mosquito, Aedes aegypti. The Journal of Pharmacology and Experimental Therapeutics. 352: 53-60. PMID 25332454 DOI: 10.1124/Jpet.114.219717  0.42
2015 Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30. PMID 25231919 DOI: 10.1007/S00213-014-3726-8  0.566
2015 Česnek M, Jansa P, Šmídková M, Mertlíková-Kaiserová H, Dračínský M, Brust TF, Pávek P, Trejtnar F, Watts VJ, Janeba Z. Cover Picture: Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin fromBordetella pertussis(ChemMedChem 8/2015) Chemmedchem. 10: 1277-1277. DOI: 10.1002/Cmdc.201590023  0.304
2014 Conley JM, Brust TF, Xu R, Burris KD, Watts VJ. Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications. Journal of Visualized Experiments : Jove. e51218. PMID 24514897 DOI: 10.3791/51218  0.55
2014 Staffend NA, Hedges VL, Chemel BR, Watts VJ, Meisel RL. Cell-type specific increases in female hamster nucleus accumbens spine density following female sexual experience. Brain Structure & Function. 219: 2071-81. PMID 23934655 DOI: 10.1007/S00429-013-0624-5  0.426
2013 Conley JM, Brand CS, Bogard AS, Pratt EP, Xu R, Hockerman GH, Ostrom RS, Dessauer CW, Watts VJ. Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. The Journal of Pharmacology and Experimental Therapeutics. 347: 276-87. PMID 24008337 DOI: 10.1124/Jpet.113.207449  0.35
2013 Conley JM, Watts VJ. Differential effects of AGS3 expression on D(2L) dopamine receptor-mediated adenylyl cyclase signaling. Cellular and Molecular Neurobiology. 33: 551-8. PMID 23504261 DOI: 10.1007/S10571-013-9925-8  0.554
2013 Ejendal KF, Conley JM, Hu CD, Watts VJ. Bimolecular fluorescence complementation analysis of G protein-coupled receptor dimerization in living cells. Methods in Enzymology. 521: 259-79. PMID 23351744 DOI: 10.1016/B978-0-12-391862-8.00014-4  0.463
2013 Hill CA, Meyer JM, Ejendal KFK, Echeverry DF, Lang EG, Avramova LV, Conley JM, Watts VJ. Re-invigorating the insecticide discovery pipeline for vector control: GPCRs as targets for the identification of next gen insecticides Pesticide Biochemistry and Physiology. 106: 141-148. DOI: 10.1016/J.Pestbp.2013.02.008  0.454
2012 Ejendal KF, Meyer JM, Brust TF, Avramova LV, Hill CA, Watts VJ. Discovery of antagonists of tick dopamine receptors via chemical library screening and comparative pharmacological analyses. Insect Biochemistry and Molecular Biology. 42: 846-53. PMID 23213654 DOI: 10.1016/J.Ibmb.2012.07.011  0.52
2012 Clark AH, McCorvy JD, Conley JM, Williams WK, Bekkam M, Watts VJ, Nichols DE. Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand. Bioorganic & Medicinal Chemistry. 20: 6366-74. PMID 23018094 DOI: 10.1016/J.Bmc.2012.08.058  0.478
2012 Ejendal KF, Dessauer CW, Hébert TE, Watts VJ. Dopamine D(2) Receptor-Mediated Heterologous Sensitization of AC5 Requires Signalosome Assembly. Journal of Signal Transduction. 2012: 210324. PMID 22523680 DOI: 10.1155/2012/210324  0.57
2012 Chemel BR, Bonner LA, Watts VJ, Nichols DE. Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists. Molecular Pharmacology. 81: 729-38. PMID 22334593 DOI: 10.1124/Mol.111.077339  0.566
2012 Meyer JM, Ejendal KF, Avramova LV, Garland-Kuntz EE, Giraldo-Calderón GI, Brust TF, Watts VJ, Hill CA. A "genome-to-lead" approach for insecticide discovery: pharmacological characterization and screening of Aedes aegypti D(1)-like dopamine receptors. Plos Neglected Tropical Diseases. 6: e1478. PMID 22292096 DOI: 10.1371/Journal.Pntd.0001478  0.374
2012 McCorvy JD, Watts VJ, Nichols DE. Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology. 222: 81-7. PMID 22222862 DOI: 10.1007/S00213-011-2625-5  0.426
2012 Cueva JP, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. European Journal of Medicinal Chemistry. 48: 97-107. PMID 22204903 DOI: 10.1016/J.Ejmech.2011.11.039  0.527
2011 Clark AH, McCorvy JD, Watts VJ, Nichols DE. Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. Bioorganic & Medicinal Chemistry. 19: 5420-31. PMID 21862338 DOI: 10.1016/J.Bmc.2011.07.057  0.518
2011 Cueva JP, Gallardo-Godoy A, Juncosa JI, Vidi PA, Lill MA, Watts VJ, Nichols DE. Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. Journal of Medicinal Chemistry. 54: 5508-21. PMID 21714510 DOI: 10.1021/Jm200334C  0.377
2011 Bonner LA, Laban U, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE. Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues. Chemmedchem. 6: 1024-40. PMID 21538900 DOI: 10.1002/Cmdc.201100010  0.494
2011 Meyer JM, Ejendal KF, Watts VJ, Hill CA. Molecular and pharmacological characterization of two D(1)-like dopamine receptors in the Lyme disease vector, Ixodes scapularis. Insect Biochemistry and Molecular Biology. 41: 563-71. PMID 21457782 DOI: 10.1016/J.Ibmb.2011.03.008  0.579
2011 Vidi PA, Ejendal KF, Przybyla JA, Watts VJ. Fluorescent protein complementation assays: new tools to study G protein-coupled receptor oligomerization and GPCR-mediated signaling. Molecular and Cellular Endocrinology. 331: 185-93. PMID 20654687 DOI: 10.1016/J.Mce.2010.07.011  0.372
2011 Clark LH, Cueva JP, McCorvy JD, Harland AA, Watts VJ, Nichols DE. C-Ring expanded analogs of doxanthrine: Conformation plays a critical role Arkivoc. 2010: 125-138. DOI: 10.3998/Ark.5550190.0011.411  0.455
2010 Bonner LA, Chemel BR, Watts VJ, Nichols DE. Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. Bioorganic & Medicinal Chemistry. 18: 6763-70. PMID 20709559 DOI: 10.1016/J.Bmc.2010.07.052  0.48
2010 Vidi PA, Przybyla JA, Hu CD, Watts VJ. Visualization of G protein-coupled receptor (GPCR) interactions in living cells using bimolecular fluorescence complementation (BiFC). Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 5.29. PMID 20373507 DOI: 10.1002/0471142301.Ns0529S51  0.407
2010 Przybyla JA, Watts VJ. Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. The Journal of Pharmacology and Experimental Therapeutics. 332: 710-9. PMID 20016021 DOI: 10.1124/Jpet.109.162701  0.524
2010 NEGASH K, NICHOLS DE, WATTS VJ, MAILMAN RB. ChemInform Abstract: Further Definition of the D1 Dopamine Receptor Pharmacophore: Synthesis of trans-6,6a,7,8,9,13b-Hexahydro-5H-benzo(d)naphth(2,1-b) azepines as Rigid Analogues of β-Phenyldopamine. Cheminform. 28: no-no. DOI: 10.1002/chin.199741209  0.307
2009 Vidi PA, Watts VJ. Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling. Molecular Pharmacology. 75: 733-9. PMID 19141658 DOI: 10.1124/Mol.108.053819  0.365
2009 Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ. Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19: 138-46. PMID 19028082 DOI: 10.1016/J.Euroneuro.2008.10.002  0.563
2008 Vidi PA, Chen J, Irudayaraj JM, Watts VJ. Adenosine A(2A) receptors assemble into higher-order oligomers at the plasma membrane. Febs Letters. 582: 3985-90. PMID 19013155 DOI: 10.1016/J.Febslet.2008.09.062  0.407
2008 Willard FS, Zheng Z, Guo J, Digby GJ, Kimple AJ, Conley JM, Johnston CA, Bosch D, Willard MD, Watts VJ, Lambert NA, Ikeda SR, Du Q, Siderovski DP. A point mutation to Galphai selectively blocks GoLoco motif binding: direct evidence for Galpha.GoLoco complexes in mitotic spindle dynamics. The Journal of Biological Chemistry. 283: 36698-710. PMID 18984596 DOI: 10.1074/Jbc.M804936200  0.345
2008 Vidi PA, Chemel BR, Hu CD, Watts VJ. Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells. Molecular Pharmacology. 74: 544-51. PMID 18524886 DOI: 10.1124/Mol.108.047472  0.455
2007 Chester JA, Watts VJ. Adenylyl cyclase 5: a new clue in the search for the "fountain of youth"? Science's Stke : Signal Transduction Knowledge Environment. 2007: pe64. PMID 18029912 DOI: 10.1126/Stke.4132007Pe64  0.38
2007 Watts VJ. Adenylyl cyclase isoforms as novel therapeutic targets: an exciting example of excitotoxicity neuroprotection. Molecular Interventions. 7: 70-3. PMID 17468386 DOI: 10.1124/Mi.7.2.6  0.333
2006 Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE. trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. Journal of Medicinal Chemistry. 49: 6848-57. PMID 17154515 DOI: 10.1021/Jm0604979  0.522
2006 Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology. 188: 244-51. PMID 16915381 DOI: 10.1007/S00213-006-0490-4  0.548
2006 Chester JA, Mullins AJ, Nguyen CH, Watts VJ, Meisel RL. Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters. Psychopharmacology. 188: 53-62. PMID 16850118 DOI: 10.1007/S00213-006-0468-2  0.694
2006 Beazely MA, Watts VJ. Regulatory properties of adenylate cyclases type 5 and 6: A progress report. European Journal of Pharmacology. 535: 1-12. PMID 16527269 DOI: 10.1016/J.Ejphar.2006.01.054  0.702
2006 Nguyen CH, Watts VJ. Dexamethasone-induced Ras protein 1 negatively regulates protein kinase C delta: implications for adenylyl cyclase 2 signaling. Molecular Pharmacology. 69: 1763-71. PMID 16489124 DOI: 10.1124/Mol.105.019133  0.695
2006 Vortherms TA, Nguyen CH, Bastepe M, Jüppner H, Watts VJ. D2 dopamine receptor-induced sensitization of adenylyl cyclase type 1 is G alpha(s) independent. Neuropharmacology. 50: 576-84. PMID 16376953 DOI: 10.1016/J.Neuropharm.2005.11.004  0.848
2005 Johnston CA, Ramer JK, Blaesius R, Fredericks Z, Watts VJ, Siderovski DP. A bifunctional Galphai/Galphas modulatory peptide that attenuates adenylyl cyclase activity. Febs Letters. 579: 5746-50. PMID 16225870 DOI: 10.1016/J.Febslet.2005.09.059  0.462
2005 Johnston CA, Willard FS, Jezyk MR, Fredericks Z, Bodor ET, Jones MB, Blaesius R, Watts VJ, Harden TK, Sondek J, Ramer JK, Siderovski DP. Structure of Galpha(i1) bound to a GDP-selective peptide provides insight into guanine nucleotide exchange. Structure (London, England : 1993). 13: 1069-80. PMID 16004878 DOI: 10.1016/J.Str.2005.04.007  0.303
2005 Watts VJ, Neve KA. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacology & Therapeutics. 106: 405-21. PMID 15922020 DOI: 10.1016/J.Pharmthera.2004.12.005  0.74
2005 Nguyen CH, Watts VJ. Dexras1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1. Biochemical and Biophysical Research Communications. 332: 913-20. PMID 15913563 DOI: 10.1016/J.Bbrc.2005.05.041  0.751
2005 Beazely MA, Watts VJ. Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation. Biochemical Pharmacology. 70: 113-20. PMID 15885660 DOI: 10.1016/J.Bcp.2005.04.007  0.769
2005 Cumbay MG, Watts VJ. Galphaq potentiation of adenylate cyclase type 9 activity through a Ca2+/calmodulin-dependent pathway. Biochemical Pharmacology. 69: 1247-56. PMID 15794946 DOI: 10.1016/J.Bcp.2005.02.001  0.807
2005 Beazely MA, Watts VJ. Activation of a novel PKC isoform synergistically enhances D2L dopamine receptor-mediated sensitization of adenylate cyclase type 6. Cellular Signalling. 17: 647-53. PMID 15683739 DOI: 10.1016/J.Cellsig.2004.10.003  0.799
2005 Beazely MA, Alan JK, Watts VJ. Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Molecular Pharmacology. 67: 250-9. PMID 15470083 DOI: 10.1124/Mol.104.001370  0.743
2004 Vortherms TA, Nguyen CH, Berlot CH, Watts VJ. Using molecular tools to dissect the role of Galphas in sensitization of AC1. Molecular Pharmacology. 66: 1617-24. PMID 15361543 DOI: 10.1124/Mol.104.000166  0.835
2004 Bradley KC, Mullins AJ, Meisel RL, Watts VJ. Sexual experience alters D1 receptor-mediated cyclic AMP production in the nucleus accumbens of female Syrian hamsters. Synapse (New York, N.Y.). 53: 20-7. PMID 15150737 DOI: 10.1002/Syn.20030  0.473
2004 Johnston CA, Beazely MA, Bilodeau ML, Andrisani O, Watts VJ. Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line. Journal of Neurochemistry. 88: 1497-508. PMID 15009651 DOI: 10.1046/J.1471-4159.2004.02285.X  0.754
2004 Cumbay MG, Watts VJ. Novel regulatory properties of human type 9 adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics. 310: 108-15. PMID 14996950 DOI: 10.1124/Jpet.104.065748  0.819
2004 Jarrahian A, Watts VJ, Barker EL. D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. The Journal of Pharmacology and Experimental Therapeutics. 308: 880-6. PMID 14634050 DOI: 10.1124/Jpet.103.057620  0.593
2004 Vortherms TA, Watts VJ. Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation. The Journal of Pharmacology and Experimental Therapeutics. 308: 221-7. PMID 14566008 DOI: 10.1124/Jpet.103.057083  0.829
2003 Lisinicchia JG, Watts VJ. Sensitization of adenylate cyclase by short-term activation of 5-HT1A receptors. Cellular Signalling. 15: 1111-7. PMID 14575866 DOI: 10.1016/S0898-6568(03)00115-3  0.551
2003 Johnston CA, Watts VJ. Sensitization of adenylate cyclase: a general mechanism of neuroadaptation to persistent activation of Galpha(i/o)-coupled receptors? Life Sciences. 73: 2913-25. PMID 14519441 DOI: 10.1016/S0024-3205(03)00703-3  0.538
2003 Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. Journal of Neurochemistry. 86: 980-91. PMID 12887695 DOI: 10.1046/J.1471-4159.2003.01921.X  0.555
2003 Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. The Journal of Pharmacology and Experimental Therapeutics. 304: 229-37. PMID 12490596 DOI: 10.1124/Jpet.102.042184  0.435
2002 Johnston CA, Beazely MA, Vancura AF, Wang JK, Watts VJ. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells. Journal of Neurochemistry. 82: 1087-96. PMID 12358756 DOI: 10.1046/J.1471-4159.2002.01033.X  0.789
2002 Watts VJ. Molecular mechanisms for heterologous sensitization of adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics. 302: 1-7. PMID 12065693 DOI: 10.1124/Jpet.302.1.1  0.555
2001 Watts VJ, Taussig R, Neve RL, Neve KA. Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Galphas: characterization of Galphas-insensitive mutants of adenylyl cyclase V. Molecular Pharmacology. 60: 1168-72. PMID 11723222 DOI: 10.1124/Mol.60.6.1168  0.766
2001 Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ, DuRand CJ, Teeter MM. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Molecular Pharmacology. 60: 373-81. PMID 11455025 DOI: 10.1124/Mol.60.2.373  0.788
2001 Johnston CA, Cumbay MG, Vortherms TA, Watts VJ. Adrenergic agonists induce heterologous sensitization of adenylate cyclase in NS20Y-D(2L) cells. Febs Letters. 497: 85-9. PMID 11377418 DOI: 10.1016/S0014-5793(01)02442-5  0.827
2001 Cumbay MG, Watts VJ. Heterologous sensitization of recombinant adenylate cyclases by activation of D(2) dopamine receptors. The Journal of Pharmacology and Experimental Therapeutics. 297: 1201-9. PMID 11356947  0.849
2000 Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. Journal of Medicinal Chemistry. 43: 4701-10. PMID 11101361 DOI: 10.1021/Jm000339W  0.772
2000 Schutzer WE, Watts VJ, Chapman J, Cumbay MG, Neve KA, Neve RL, Mader SL. Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity. Clinical and Experimental Pharmacology & Physiology. 27: 9-13. PMID 10696522 DOI: 10.1046/J.1440-1681.2000.03210.X  0.766
1999 Watts VJ, Vu MN, Wiens BL, Jovanovic V, Van Tol HH, Neve KA. Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors. Psychopharmacology. 141: 83-92. PMID 9952069 DOI: 10.1007/S002130050810  0.731
1998 Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 8692-9. PMID 9786976  0.831
1998 Lewis MM, Watts VJ, Lawler CP, Nichols DE, Mailman RB. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. The Journal of Pharmacology and Experimental Therapeutics. 286: 345-53. PMID 9655879  0.512
1998 Watts VJ, Wiens BL, Cumbay MG, Vu MN, Neve RL, Neve KA. Selective Activation of Gαoby D2LDopamine Receptors in NS20Y Neuroblastoma Cells The Journal of Neuroscience. 18: 8692-8699. DOI: 10.1523/Jneurosci.18-21-08692.1998  0.827
1997 Watts VJ, Neve KA. Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors. Molecular Pharmacology. 52: 181-6. PMID 9271339 DOI: 10.1124/Mol.52.2.181  0.749
1997 Negash K, Nichols DE, Watts VJ, Mailman RB. Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine. Journal of Medicinal Chemistry. 40: 2140-7. PMID 9216832 DOI: 10.1021/Jm970157A  0.468
1996 Watts VJ, Neve KA. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors. Molecular Pharmacology. 50: 966-76. PMID 8863843  0.765
1996 Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, Mailman RB. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. Journal of Medicinal Chemistry. 39: 285-96. PMID 8568818 DOI: 10.1021/Jm9502100  0.468
1996 Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. Journal of Medicinal Chemistry. 39: 549-55. PMID 8558526 DOI: 10.1021/Jm950707+  0.532
1996 Neve KA, Watts VJ. Heterologous sensitization of adenylate cyclase by Gj-coupled receptors Faseb Journal. 10: A133.  0.382
1995 Lawler CP, Gilmore JH, Watts VJ, Walker QD, Southerland SB, Cook LL, Mathis CA, Mailman RB. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model. Synapse (New York, N.Y.). 21: 299-311. PMID 8869160 DOI: 10.1002/Syn.890210404  0.415
1995 Watts VJ, Lawler CP, Gonzales AJ, Zhou QY, Civelli O, Nichols DE, Mailman RB. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse (New York, N.Y.). 21: 177-87. PMID 8584979 DOI: 10.1002/syn.890210211  0.53
1995 Brewster WK, Nichols DE, Watts VJ, Riggs RM, Mottola D, Mailman RB. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. Journal of Medicinal Chemistry. 38: 318-27. PMID 7830274 DOI: 10.1021/Jm00002A013  0.503
1995 Knoerzer TA, Watts VJ, Nichols DE, Mailman RB. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. Journal of Medicinal Chemistry. 38: 3062-70. PMID 7636869 DOI: 10.1021/Jm00016A009  0.473
1995 Snyder SE, Aviles-Garay FA, Chakraborti R, Nichols DE, Watts VJ, Mailman RB. Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine. Journal of Medicinal Chemistry. 38: 2395-409. PMID 7608904 DOI: 10.1021/Jm00013A015  0.441
1995 Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology. 118: 401-9. PMID 7568626 DOI: 10.1007/Bf02245940  0.71
1995 Gilmore JH, Watts VJ, Lawler CP, Noll EP, Nichols DE, Mailman RB. "Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications. Neuropharmacology. 34: 481-8. PMID 7566481 DOI: 10.1016/0028-3908(95)00014-W  0.445
1994 Minor DL, Wyrick SD, Charifson PS, Watts VJ, Nichols DE, Mailman RB. Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. Journal of Medicinal Chemistry. 37: 4317-28. PMID 7996543 DOI: 10.1021/Jm00051A008  0.485
1994 Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, Mailman RB. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. Journal of Medicinal Chemistry. 37: 2453-60. PMID 7914538 DOI: 10.1021/Jm00041A025  0.536
1993 Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB. Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. European Journal of Pharmacology. 239: 271-3. PMID 8223910 DOI: 10.1016/0014-2999(93)91012-C  0.724
1993 Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB. Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. European Journal of Pharmacology. 242: 165-72. PMID 7902811 DOI: 10.1016/0014-2999(93)90076-T  0.445
Show low-probability matches.